These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31557260)

  • 1. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.
    Ebert K; Mattes J; Kunzke T; Zwingenberger G; Luber B
    PLoS One; 2019; 14(9):e0223225. PubMed ID: 31557260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
    Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
    Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.
    Keller S; Zwingenberger G; Ebert K; Hasenauer J; Wasmuth J; Maier D; Haffner I; Schierle K; Weirich G; Luber B
    Mol Oncol; 2018 Apr; 12(4):441-462. PubMed ID: 29325228
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
    Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
    Ebert K; Zwingenberger G; Barbaria E; Keller S; Heck C; Arnold R; Hollerieth V; Mattes J; Geffers R; Raimúndez E; Hasenauer J; Luber B
    BMC Cancer; 2020 Oct; 20(1):1039. PubMed ID: 33115415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
    Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
    Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
    Ebert K; Haffner I; Zwingenberger G; Keller S; Raimúndez E; Geffers R; Wirtz R; Barbaria E; Hollerieth V; Arnold R; Walch A; Hasenauer J; Maier D; Lordick F; Luber B
    BMC Cancer; 2022 Mar; 22(1):254. PubMed ID: 35264144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
    Kim S; Kim TM; Kim DW; Kim S; Kim M; Ahn YO; Keam B; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):951-962. PubMed ID: 30309221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Afatinib and Lapatinib Against
    Nakata S; Fujita M; Nakanishi H
    Anticancer Res; 2019 Nov; 39(11):5927-5932. PubMed ID: 31704817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
    Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
    Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
    Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
    J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
    Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
    Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
    Ji F; Liu X; Wu Y; Fang X; Huang G
    Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial approaches targeting the EGFR family and c-Met in SCCHN.
    Wang D; Lu Y; Nannapaneni S; Griffith CC; Steuer C; Qian G; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; He X; Chen ZG; Saba NF
    Oral Oncol; 2021 Jan; 112():105074. PubMed ID: 33142224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.
    Yoshioka T; Shien K; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Asano H; Soh J; Tsukuda K; Nagasaka T; Fujiwara T; Toyooka S
    Cancer Sci; 2018 Apr; 109(4):1166-1176. PubMed ID: 29465762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of CALM2 increases the sensitivity to afatinib in HER2-amplified gastric cancer cells by regulating the Akt/FoxO3a/Puma axis.
    Sun J; Cao Q; Lin S; Chen Y; Liu X; Hong Q
    Toxicol In Vitro; 2023 Mar; 87():105531. PubMed ID: 36460225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
    De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
    Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
    Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
    Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.